These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2491941)

  • 1. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
    Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP
    Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. l-Deprenyl in atypical depressives.
    Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO
    Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
    Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?
    Mendis N; Pare CM; Sandler M; Glover V; Stern GM
    Psychopharmacology (Berl); 1981; 73(1):87-90. PubMed ID: 6785797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical effects of L-deprenyl in atypical depressives.
    Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
    Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose selegiline in treatment-resistant older depressive patients.
    Sunderland T; Cohen RM; Molchan S; Lawlor BA; Mellow AM; Newhouse PA; Tariot PN; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1994 Aug; 51(8):607-15. PubMed ID: 7519005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
    Mendlewicz J; Youdim MB
    Br J Psychiatry; 1983 May; 142():508-11. PubMed ID: 6409196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S
    J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883
    [No Abstract]   [Full Text] [Related]  

  • 11. Tyramine pressor sensitivity changes during deprenyl treatment.
    Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
    Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled trial of L-deprenyl in atypical depression.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
    Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
    [No Abstract]   [Full Text] [Related]  

  • 14. Absence of "cheese effect" during deprenyl therapy: some recent studies.
    Sandler M; Glover V; Ashford A; Stern GM
    J Neural Transm; 1978; 43(3-4):209-15. PubMed ID: 745013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
    Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
    Murphy DL; Karoum F; Pickar D; Cohen RM; Lipper S; Mellow AM; Tariot PN; Sunderland T
    J Neural Transm Suppl; 1998; 52():39-48. PubMed ID: 9564606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
    Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.